Učitavanje...

Development of a Highly Selective Allosteric Antagonist Radioligand for the Type 1 Cholecystokinin Receptor and Elucidation of Its Molecular Basis of Binding

Understanding the molecular basis of ligand binding to receptors provides insights useful for rational drug design. This work describes development of a new antagonist radioligand of the type 1 cholecystokinin receptor (CCK1R), (2-fluorophenyl)-2,3-dihydro-3-[(3-isoquinolinylcarbonyl)amino]-6-methox...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Pharmacol
Glavni autori: Dong, Maoqing, Vattelana, Ashton M., Lam, Polo C.-H., Orry, Andrew J., Abagyan, Ruben, Christopoulos, Arthur, Sexton, Patrick M., Haines, David R., Miller, Laurence J.
Format: Artigo
Jezik:Inglês
Izdano: The American Society for Pharmacology and Experimental Therapeutics 2015
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4279081/
https://ncbi.nlm.nih.gov/pubmed/25319540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.114.095430
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!